全文获取类型
收费全文 | 813篇 |
免费 | 71篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 27篇 |
妇产科学 | 21篇 |
基础医学 | 98篇 |
口腔科学 | 29篇 |
临床医学 | 97篇 |
内科学 | 152篇 |
皮肤病学 | 8篇 |
神经病学 | 18篇 |
特种医学 | 142篇 |
外科学 | 99篇 |
综合类 | 24篇 |
预防医学 | 56篇 |
眼科学 | 6篇 |
药学 | 73篇 |
肿瘤学 | 49篇 |
出版年
2021年 | 12篇 |
2020年 | 6篇 |
2019年 | 7篇 |
2018年 | 7篇 |
2017年 | 8篇 |
2016年 | 12篇 |
2015年 | 6篇 |
2014年 | 19篇 |
2013年 | 23篇 |
2012年 | 21篇 |
2011年 | 23篇 |
2010年 | 17篇 |
2009年 | 23篇 |
2008年 | 28篇 |
2007年 | 36篇 |
2006年 | 23篇 |
2005年 | 26篇 |
2004年 | 21篇 |
2003年 | 18篇 |
2002年 | 25篇 |
2001年 | 11篇 |
2000年 | 18篇 |
1999年 | 17篇 |
1998年 | 39篇 |
1997年 | 20篇 |
1996年 | 25篇 |
1995年 | 21篇 |
1994年 | 26篇 |
1993年 | 17篇 |
1992年 | 20篇 |
1991年 | 20篇 |
1990年 | 23篇 |
1989年 | 32篇 |
1988年 | 39篇 |
1987年 | 21篇 |
1986年 | 25篇 |
1985年 | 26篇 |
1984年 | 20篇 |
1983年 | 9篇 |
1982年 | 14篇 |
1981年 | 6篇 |
1980年 | 14篇 |
1979年 | 6篇 |
1978年 | 5篇 |
1977年 | 9篇 |
1976年 | 9篇 |
1972年 | 6篇 |
1971年 | 5篇 |
1968年 | 4篇 |
1967年 | 4篇 |
排序方式: 共有902条查询结果,搜索用时 15 毫秒
1.
Pharmacokinetic interactions of cimetidine 1987 总被引:4,自引:0,他引:4
The number of studies on drug interactions with cimetidine has increased at a rapid rate over the past 5 years, with many of the interactions being solely pharmacokinetic in origin. Very few studies have investigated the clinical relevance of such pharmacokinetic interactions by measuring pharmacodynamic responses or clinical endpoints. Apart from pharmacokinetic studies, invariably conducted in young, healthy subjects, there have been a large number of in vitro and in vivo animal studies, case reports, clinical observations and general reviews on the subject, which is tending to develop an industry of its own accord. Nevertheless, where specific mechanisms have been considered, these have undoubtedly increased our knowledge on the way in which humans eliminate xenobiotics. There is now sufficient information to predict the likelihood of a pharmacokinetic drug-drug interaction with cimetidine and to make specific clinical recommendations. Pharmacokinetic drug interactions with cimetidine occur at the sites of gastrointestinal absorption and elimination including metabolism and excretion. Cimetidine has been found to reduce the plasma concentrations of ketoconazole, indomethacin and chlorpromazine by reducing their absorption. In the case of ketoconazole the interaction was clinically important. Cimetidine does not inhibit conjugation mechanisms including glucuronidation, sulphation and acetylation, or deacetylation or ethanol dehydrogenation. It binds to the haem portion of cytochrome P-450 and is thus an inhibitor of phase I drug metabolism (i.e. hydroxylation, dealkylation). Although generally recognised as a nonspecific inhibitor of this type of metabolism, cimetidine does demonstrate some degree of specificity. To date, theophylline 8-oxidation, tolbutamide hydroxylation, ibuprofen hydroxylation, misonidazole demethylation, carbamazepine epoxidation, mexiletine oxidation and steroid hydroxylation have not been shown to be inhibited by cimetidine in humans but the metabolism of at least 30 other drugs is affected. Recent evidence indicates negligible effects of cimetidine on liver blood flow. Cimetidine reduces the renal clearance of drugs which are organic cations, by competing for active tubular secretion in the proximal tubule of the kidney, reducing the renal clearances of procainamide, ranitidine, triamterene, metformin, flecainide and the active metabolite N-acetylprocainamide. This previously unrecognised form of drug interaction with cimetidine may be clinically important for both parent drug, and metabolites which may be active.(ABSTRACT TRUNCATED AT 400 WORDS) 相似文献
2.
E E Muirhead L W Byers B Brooks J A Pitcock P Brown R Dowell 《The American journal of the medical sciences》1987,294(5):384-387
Selachyl alcohol (SA) is a mono-oleyl glyceryl ether. It has certain biologic activities similar to those of the antihypertensive neutral renomedullary lipid (ANRL) derived from the renal papilla and its renomedullary interstitial cells (RIC). These include a vaso-depressor effect following bolus injection and a requirement for hepatic activation for the development of biological activity. In view of this similarity to ANRL, it appeared worthwhile to test the antihypertensive action of SA when given via the GI tract. Accordingly, pure SA was given either by gavage or by tube into the stomach or duodenum of one-kidney, one-clip hypertensive rats (5-10 mg per dose). The role of hepatic activation was demonstrated by comparing the BP response to bolus injection of SA and ANRL with and without the presence of an intact circulation to the liver. Administration of SA via the GI tract resulted in a significant decline in BP without tachycardia or weight loss. In the absence of a circulation to the liver, neither SA nor ANRL was active. SA appears to be an effective antihypertensive agent when given via the GI tract. 相似文献
3.
4.
The multidrug resistance transport protein is a normal constituent of the liver canalicular membrane, although its function has not been defined in vivo. Colchicine, a multidrug resistance substrate, is eliminated mainly by the liver. Cyclosporine reverses multidrug resistance in vitro, presumably by inhibiting the multidrug resistance transporter. This study assesses biliary colchicine elimination and the effect of cyclosporine on this process. After cyclosporine administration biliary colchicine clearance decreased from 11.6 +/- 0.8 to 2.2 +/- 0.4 ml/min.kg (p less than 0.05), and the colchicine bile/plasma ratio decreased from 166 +/- 9 to 38 +/- 5 (p less than 0.05). Cremophor EL (a cyclosporine vehicle) transiently inhibited biliary colchicine clearance and colchicine bile/plasma ratio, but to a much smaller extent than cyclosporine in vehicle. Biliary cyclosporine clearance was 0.122 and 0.024 ml/min.kg after bolus doses of 2 or 10 mg/kg intravenously, respectively. Cyclosporine bile/plasma ratio was 1.3 to 5.2. When cyclosporine was given 16 hr before colchicine infusion, biliary colchicine clearance decreased 39% (p less than 0.05), and colchicine bile/plasma ratio decreased 51% (p less than 0.05). Thus colchicine is actively secreted into bile and will be useful in the study of the multidrug transporter in vivo. Cyclosporine profoundly inhibits colchicine secretion into bile but is itself mainly metabolized rather than secreted. If competition for a common carrier is the basis for the interaction, then cyclosporine represents a drug that binds to but is not transported by the canalicular transporter. 相似文献
5.
6.
E. Eric Muirhead David H. P. Streeten Bennie Brooks Edward T. Schroeder Lawrence W. Byers 《Blood pressure》1992,1(3):138-148
A new syndrome is described in a patient with advanced renal insufficiency. This consists of severe and persistent hypotension causing weakness but associated with a clear mental status. Also present is evidence for decreased vascular reactivity. The hypotension was not orthostatic. The hypotension was associated with a circulating vasodepressor substance having the characteristics of medullipin I. The medullipin appears to have been derived from the remaining right kidney. Hypotension existed despite the presence of major prohypertensive mechanisms, including an endstage kidney, hyperreninemia and hyperaldosteronemia. It is likely that hypotension due to hypermedullipinemia is an entity occurring in the human being. 相似文献
7.
8.
9.
10.